{
    "clinical_study": {
        "@rank": "23463", 
        "acronym": "PI3K", 
        "arm_group": {
            "arm_group_label": "RP6530", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K\n      delta/gamma inhibitor in patients with hematologic malignancies."
        }, 
        "brief_title": "Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lymphoma, B-Cell", 
            "T-Cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, T-Cell", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Refractory to or relapsed after at least 1 prior treatment line.\n\n          -  ECOG performance status \u22642\n\n          -  Patients must be \u226518 years of age\n\n          -  Able to give a written informed consent.\n\n        Exclusion Criteria:\n\n          -  Any cancer therapy in the last 4 weeks or limited palliative radiation <2 weeks\n\n          -  Patients with HBV, HCV or HIV infection\n\n          -  Autologous hematologic stem cell transplant within 3 months of study entry.\n             Allogeneic hematologic stem cell transplant within 12 months.\n\n          -  Previous therapy with GS-1101 (CAL-101, idelalisib), IPI-145, TGR-1202 or any drug\n             that specifically inhibits PI3K/ mTOR (including temsirolimus, everolimus), AKT or\n             BTK Inhibitor (including Ibrutinib).\n\n          -  Patients on immunosuppressive therapy including systemic corticosteroids.\n\n          -  Patients who are receiving chronic systemic anticoagulation therapy (warfarin sodium\n             or heparin, etc.).\n\n          -  Patients with known history of liver disorders.\n\n          -  Patients with uncontrolled Diabetes Type I or Type II\n\n          -  Any severe and/or uncontrolled medical conditions or other conditions that could\n             affect their participation in the study.\n\n          -  Women who are pregnant or lactating."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017613", 
            "org_study_id": "RP6530-1301", 
            "secondary_id": "2013-003769-32"
        }, 
        "intervention": {
            "arm_group_label": "RP6530", 
            "description": "Escalating doses starting at 25 mg BID", 
            "intervention_name": "RP6530", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "CLL, SLL, NHL, SLL, PTCL, CTCL, MM, AML", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "last_name": "Rhizen Trial Site, Milano"
            }, 
            "facility": {
                "address": {
                    "city": "Milano", 
                    "country": "Italy"
                }, 
                "name": "Rhizen Trial Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies", 
        "overall_contact": {
            "email": "clinicaltrials@rhizen.com", 
            "last_name": "Clinical Support", 
            "phone": "+41 32 580 0113"
        }, 
        "overall_official": {
            "affiliation": "Ospedale San Raffaele s.r.l.", 
            "last_name": "Andr\u00e9s J. M. Ferreri, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To access maximum tolerated dose by clinical laboratory assessments, adverse events and dose limiting toxicities.", 
                "measure": "To determine the maximum tolerated dose of RP6530 in patients with hematological malignancies", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Pharmacokinetic parameters AUC, Cmax, tmax, t1/2 will be determined", 
                "measure": "To evaluate the Pharmacokinetics of RP6530", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess efficacy parameters", 
            "measure": "To evaluate the clinical response following administration of RP6530 in patients with hematological malignancies", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Rhizen Pharmaceuticals SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rhizen Pharmaceuticals SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}